Malta - English - Medicines Authority

remedica limited limassol industrial estate, aharnon street, 3056 limassol, cyprus - mianserin hydrochloride - film-coated tablet - mianserin hydrochloride 10 mg - psychoanaleptics

Malta - English - Medicines Authority

mylan ireland limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - mianserin hydrochloride - film-coated tablet - mianserin hydrochloride 10 mg - psychoanaleptics

Malta - English - Medicines Authority

mylan ireland limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - mianserin hydrochloride - film-coated tablet - mianserin hydrochloride 30 mg - psychoanaleptics

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - baricitinib, quantity: 4 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; mannitol; microcrystalline cellulose; polyvinyl alcohol; titanium dioxide; macrogol 3350; purified talc; lecithin; iron oxide red - rheumatoid arthritis,olumiant is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately, or who are intolerant, to one or more dmards.,olumiant can be taken as monotherapy or in combination with cdmards, including methotrexate (mtx).,atopic dermatitis,olumiant is indicated for the treatment of moderate to severe atopic dermatitis (ad) in adult patients who are candidates for systemic therapy.,alopecia areata,olumiant is indicated for the treatment of severe alopecia areata (aa) in adult patients in whom other treatments have failed or are not appropriate and no spontaneous improvement is observed (see section 5.1 pharmacodynamic properties; clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - baricitinib, quantity: 2 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; mannitol; microcrystalline cellulose; polyvinyl alcohol; titanium dioxide; macrogol 3350; purified talc; lecithin; iron oxide red - rheumatoid arthritis,olumiant is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately, or who are intolerant, to one or more dmards.,olumiant can be taken as monotherapy or in combination with cdmards, including methotrexate (mtx).,atopic dermatitis,olumiant is indicated for the treatment of moderate to severe atopic dermatitis (ad) in adult patients who are candidates for systemic therapy.,alopecia areata,olumiant is indicated for the treatment of severe alopecia areata (aa) in adult patients in whom other treatments have failed or are not appropriate and no spontaneous improvement is observed (see section 5.1 pharmacodynamic properties; clinical trials).

Malta - English - Medicines Authority

remedica limited limassol industrial estate, aharnon street, 3056 limassol, cyprus - mianserin hydrochloride - film-coated tablet - mianserin hydrochloride 30 mg - psychoanaleptics

Australia - English - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - dapoxetine hydrochloride, quantity: 33.6 mg (equivalent: dapoxetine, qty 30 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; titanium dioxide; colloidal anhydrous silica; magnesium stearate; lactose monohydrate; iron oxide yellow; microcrystalline cellulose; hypromellose; triacetin; iron oxide black - priligy is indicated for the treatment of premature ejaculation (pe) in men 18 to 64 years of age, who have all of the following: an intravaginal ejaculatory latency time (ielt) of less than two minutes; and persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after penetration and before the patient wishes; and marked personal distress or interpersonal difficulty as a consequence of pe; and poor control over ejaculation.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - naltrexone hydrochloride, quantity: 50 mg - tablet, film coated - excipient ingredients: titanium dioxide; powdered cellulose; lactose monohydrate; microcrystalline cellulose; iron oxide black; crospovidone; iron oxide yellow; colloidal anhydrous silica; iron oxide red; hypromellose; macrogol 4000; magnesium stearate - naltrexone gh is indicated for use within a comprehensive treatment programme for alcohol dependence. naltrexone gh is also indicated as adjunctive therapy in the maintenance of formerly opioid-dependent patients who have ceased the use of opioids such as diamorphine (heroin) and morphine.

Australia - English - Department of Health (Therapeutic Goods Administration)

norgine pty ltd - rifaximin, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; glyceryl isostearate; sodium starch glycollate type a; colloidal anhydrous silica; purified talc; hypromellose; titanium dioxide; disodium edetate; propylene glycol; iron oxide red - xifaxan is indicated for the treatment of patients ( > = 12 years of age) with travellers? diarrhoea caused by non-invasive strains of escherichia coli (see ?precautions?, and ?clinical trials? ). travellers? diarrhoea describes a clinical picture predominantly observed in subjects travelling from developed to developing countries. it is most frequently caused by enterotoxigenic escherichia coli (etec), enteroaggregative e. coli (eaec) and other non-invasive pathogens.

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - mianserin hydrochloride - film-coated tablet - mianserin hydrochloride 30 mg - psychoanaleptics